Small-Molecule AhR Ligands for Selective Tr1 Cell Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune-suppressing drug therapies for autoimmune diseases, such as type 1 diabetes and graft versus host disease, cause severe side effects like increased infection risk and cancer due to nonspecific inhibition of cellular proliferation, while targeting T cells specifically to induce regulatory T cells is a promising but underdeveloped therapeutic strategy.
Innovation Solution
Development of non-toxic, small molecule aryl hydrocarbon receptor (AhR) ligands that induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing general immune suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune-suppressing drug therapies are used to treat autoimmune diseases, then the pathogenic immune responses are suppressed, but nonspecific immune suppression occurs leading to increased infection risk and cancer
Solution Approach 1:
The invention segments the immune system response by specifically targeting T cell differentiation pathways rather than suppressing all immune cells. The AhR ligands selectively induce Tr1 cell differentiation from naive T cells, creating a segmented approach that suppresses pathogenic responses while preserving other immune functions.
Solution Approach 2:
The aryl hydrocarbon receptor (AhR) serves as an intermediary target that mediates selective immune modulation. By activating AhR with specific ligands, the invention creates an intermediate signaling pathway that leads to Tr1 cell differentiation and pathogenic response suppression without direct nonspecific immune cell suppression.
2Reliability
If T cells are specifically targeted to induce regulatory T cells, then pathogenic immune responses are suppressed, but the therapeutic strategy remains underdeveloped without effective small molecule ligands
Solution Approach 1:
The invention changes the chemical parameters of AhR ligands by developing novel small molecule compounds with optimized structures. The compounds feature specific molecular configurations (e.g., dibenzofuran, indole rings with nitrogen-containing six-membered rings) that enhance AhR binding affinity and selectivity, making the therapeutic strategy practically implementable.
Solution Approach 2:
The AhR ligands are composite molecular structures combining multiple functional moieties (aromatic rings, nitrogen-containing heterocycles, carbonyl groups) that work synergistically to activate the AhR pathway and induce Tr1 cell differentiation.
3Reliability
If AhR ligands are developed to induce Tr1 cell differentiation, then pathogenic immune responses are suppressed, but the ligands must be non-toxic with favorable pharmacokinetic properties
Solution Approach 1:
The AhR ligands exhibit local quality by demonstrating high selectivity for AhR activation in immune cells while maintaining low toxicity in other tissues. The molecular structures are designed to preferentially interact with AhR in T cells, producing localized immune modulation effects without systemic toxicity.
Solution Approach 2:
The small molecule AhR ligands are designed as metabolically stable but not permanently accumulating compounds. They exert their therapeutic effect during their pharmacokinetic half-life and are then cleared from the body, avoiding long-term toxicity while maintaining effective suppression of autoimmune responses during treatment.
Data Source
AI summary
Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.